XML 45 R20.htm IDEA: XBRL DOCUMENT v3.21.1
Trade and Other Payables
12 Months Ended
Dec. 31, 2020
Disclosure Of Trade And Other Payables [Abstract]  
Trade and Other Payables

14.

TRADE AND OTHER PAYABLES

Trade and other payables consisted of the following:

 

Trade and other payables - Total

 

As of

 

(in € thousands)

 

2018/12/31

 

 

2019/12/31

 

 

2020/12/31

 

Trade payables (*)

 

 

32,649

 

 

 

32,753

 

 

 

20,337

 

Social security costs payables

 

 

2,967

 

 

 

3,598

 

 

 

4,477

 

VAT payables

 

 

1

 

 

 

2

 

 

 

314

 

Taxes payables

 

 

286

 

 

 

487

 

 

 

319

 

Other payables

 

 

71

 

 

 

527

 

 

 

569

 

TOTAL

 

 

35,974

 

 

 

37,368

 

 

 

26,015

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Trade and other payables - Current

 

As of

 

(in € thousands)

 

2018/12/31

 

 

2019/12/31

 

 

2020/12/31

 

Trade payables

 

 

32,649

 

 

 

32,753

 

 

 

20,337

 

Social security costs payables

 

 

2,967

 

 

 

3,598

 

 

 

4,477

 

VAT payables

 

 

1

 

 

 

2

 

 

 

314

 

Taxes payables

 

 

286

 

 

 

487

 

 

 

319

 

Other payables

 

 

71

 

 

 

76

 

 

 

118

 

TOTAL

 

 

35,974

 

 

 

36,917

 

 

 

25,564

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Trade and other payables - Non current

 

As of

 

(in € thousands)

 

2018/12/31

 

 

2019/12/31

 

 

2020/12/31

 

Trade payables

 

 

 

 

 

 

 

 

 

Social security costs payables

 

 

 

 

 

 

 

 

 

VAT payables

 

 

 

 

 

 

 

 

 

Taxes payables

 

 

 

 

 

 

 

 

 

Other payables

 

 

(0

)

 

 

450

 

 

 

451

 

TOTAL

 

 

(0

)

 

 

450

 

 

 

451

 

 

 

 

 

 

 

 

 

 

 

 

 

 

(*) Of which : Accrued expenses

 

 

19,395

 

 

 

18,682

 

 

 

13,809

 

 

 

A very significant part of the accrued expenses reflects the estimation of the expected invoicing by the clinical trial sites via the Clinical Research Organization in charge of the RESOLVE-IT study ($9.6 million and €2.3 million, i.e. a total of €10.1 million based on the exchange rate at December 31, 2020). The timeframe in which those invoices will be received by the Company is unknown and may be spread out over a long period after the services have been performed.

In 2019, the CRO ( Clinical Research Organization) commissioned as part of the RESOLVE IT trial updated its investigators costs estimation model by referring certain assumptions on the basis of historical data. These changes constitute a change in accounting estimate within the meaning of IAS 8 and have led in 2019 to a reduction in the amount recognized for invoices not received related to this specific costs in an amount of €6,994 compared to the previous model.